Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology

American Association for Cancer Research. (2015). Proceedings: AACR 106th Annual Meeting 2015. Philadelphia. Cancer Res. 75, 15 Supplement. American Association for Cancer Research. (2017). CICR: general resources. Resources for understanding the proper use of chemical tools in cancer research. http://www.aacr.org/MEMBERSHIP/PAGES/SCIENTIFIC%20WORKING%20GROUPS/CICR-GENERAL-RESOURCES.ASPX#.WKTFQ_4SHbi. Accessed March 16, 2017. Arrowsmith, 2015, The promise and peril of chemical probes, Nat. Chem. Biol., 11, 536, 10.1038/nchembio.1867 Ashworth, 2008, A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair, J. Clin. Oncol., 26, 3785, 10.1200/JCO.2008.16.0812 Baell, 2010, New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays, J. Med. Chem., 53, 2719, 10.1021/jm901137j Baell, 2014, Chemical con artists foil drug discovery, Nature, 513, 481, 10.1038/513481a Baker, 2013, Fragment-based lead discovery grows up, Nat. Rev. Drug Discov., 12, 5, 10.1038/nrd3926 Banerji, 2016, Critical parameters in targeted drug development: the pharmacological audit trail, Semin. Oncol., 43, 436, 10.1053/j.seminoncol.2016.06.001 Barelier, 2015, The recognition of identical ligands by unrelated proteins, ACS Chem. Biol., 10, 2772, 10.1021/acschembio.5b00683 Baud, 2014, A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes, Science, 346, 638, 10.1126/science.1249830 Begley, 2012, Drug development: raise standards for preclinical cancer research, Nature, 483, 531, 10.1038/483531a Bishop, 2000, A chemical switch for inhibitor-sensitive alleles of any protein kinase, Nature, 407, 395, 10.1038/35030148 Blagg, 2006, Structure-activity relationships for in vitro and in vivo toxicity, Annu. Rep. Med. Chem., 41, 353 Blagg, 2010, Structural alerts for toxicity, 301 Blagg, 2014, Chemical biology approaches to target validation in cancer, Curr. Opin. Pharmacol., 17, 87, 10.1016/j.coph.2014.07.007 Blevitt, 2017, Structural basis of small-molecule aggregate induced inhibition of a protein–protein interaction, J. Med. Chem., 60, 3511, 10.1021/acs.jmedchem.6b01836 Blum, 2009, 970 million druglike small molecules for virtual screening in the chemical universe database GDB-13, J. Am. Chem. Soc., 131, 8732, 10.1021/ja902302h Bondeson, 2015, Catalytic in vivo protein knockdown by small molecule PROTACs, Nat. Chem. Biol., 11, 611, 10.1038/nchembio.1858 Bordeaux, 2010, Antibody validation, BioTechniques, 48, 197, 10.2144/000113382 Bottcher, 2016, An additive definition of molecular complexity, J. Chem. Inf. Model., 56, 462, 10.1021/acs.jcim.5b00723 Bowes, 2012, Reducing safety-related drug attrition: the use of in vitro pharmacological profiling, Nat. Rev. Drug Discov., 11, 909, 10.1038/nrd3845 Bruns, 2012, Rules for identifying potentially reactive or promiscuous compounds, J. Med. Chem., 55, 9763, 10.1021/jm301008n Bunnage, 2013, Target validation using chemical probes, Nat. Chem. Biol., 9, 195, 10.1038/nchembio.1197 2015, Pharmacogenomic agreement between two cancer cell line data sets, Nature, 528, 84, 10.1038/nature15736 Capuzzi, 2017, Phantom PAINS: problems with the utility of alerts for pan-assay interference compounds, J. Chem. Inf. Model., 57, 417, 10.1021/acs.jcim.6b00465 Chakraborty, 2010, Characterization of the 4-(Benzothiazol-2-yl)phenylnitrenium ion from a putative metabolite of a model antitumor drug, J. Org. Chem., 75, 5296, 10.1021/jo101275y Chemical Probes Portal. (2017a). Portal News: Rigorous evaluation of chemical probes advances drug discovery efforts. http://us12.campaign-archive2.com/?u=26d744443f0b394b8c0a3ba6d&id=9c39807005#mctoc1. Accessed March 16, 2017. Chemical Probes Portal. (2017b). Historic Compounds. http://www.chemicalprobes.org/historic-compounds. Accessed March 16, 2017. Chemical Probes Portal. (2017c). Homepage. http://www.chemicalprobes.org. Accessed March 16, 2017. Cho, 2016, On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models, Nature, 539, 107, 10.1038/nature19795 Ciceri, 2014, Dual kinase-bromodomain inhibitors for rationally designed polypharmacology, Nat. Chem. Biol., 10, 305, 10.1038/nchembio.1471 Collins, 2014, Policy: NIH plans to enhance reproducibility, Nature, 505, 612, 10.1038/505612a Curpăn, 2014, Exploring the biological promiscuity of high-throughput screening hits through DFT calculations, Bioorg. Med. Chem., 22, 2461, 10.1016/j.bmc.2014.02.055 Dale, 2015, Identification of a potent and selective chemical probe for exploring the role of Mediator complex-associated protein kinases CDK8 and CDK19 in human disease, Nat. Chem. Biol., 11, 973, 10.1038/nchembio.1952 de Haard, 1999, A large non-immunized human fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies, J. Biol. Chem., 274, 18218, 10.1074/jbc.274.26.18218 Dittmann, 2014, The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains, ACS Chem. Biol., 9, 495, 10.1021/cb400789e Doudna, 2014, The new frontier of genome engineering with CRISPR-Cas9, Science, 346, 1258096, 10.1126/science.1258096 Ember, 2014, Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors, ACS Chem. Biol., 9, 1160, 10.1021/cb500072z Eng, 2016, Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy, Proc. Natl. Acad. Sci. USA, 113, 182, 10.1073/pnas.1515617113 Engel, 2015, Hope and disappointment: covalent inhibitors to overcome drug resistance in non-small cell lung cancer, ACS Med. Chem. Lett., 7, 2, 10.1021/acsmedchemlett.5b00475 Enthammer, 2013, Isolation of a novel thioflavin s–derived compound that inhibits bag-1–mediated protein interactions and targets BRAF inhibitor–resistant cell lines, Mol. Cancer Ther., 12, 2400, 10.1158/1535-7163.MCT-13-0142 Eurofins/CEREP. (2017). Standard profiles. http://www.cerep.fr/cerep/users/pages/catalog/profiles/catalog.asp. Accessed March 16, 2017. European Monoclonal Antibodies Network. (2017). EuroMabNet: European monoclonal antibodies network. https://www.euromabnet.com/. Accessed May 16, 2017. Evans, 2015, Investigating apoptozole as a chemical probe for HSP70 inhibition, PLoS One, 10, e0140006, 10.1371/journal.pone.0140006 Extance, A. (2015). Pfizer's Response to Compound Fraud Spotlights Quality Issues. RSC Chemistry World, 7th December 2015. Filippakopoulos, 2014, Targeting bromodomains: epigenetic readers of lysine acetylation, Nat. Rev. Drug Discov., 13, 337, 10.1038/nrd4286 Filippakopoulos, 2010, Selective inhibition of BET bromodomains, Nature, 468, 1067, 10.1038/nature09504 Finlay, 2014, Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor, J. Med. Chem., 57, 8249, 10.1021/jm500973a Fischer, 2014, Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide, Nature, 512, 49, 10.1038/nature13527 Frearson, 2010, Drug discovery in academia: the third way, Expert Opin. Drug Discov., 5, 909, 10.1517/17460441.2010.506508 Frye, 2010, The art of the chemical probe, Nat. Chem. Biol., 6, 159, 10.1038/nchembio.296 Frye, 2011, US Academic drug discovery, Nat. Rev. Drug Discov., 10, 409, 10.1038/nrd3462 Frye, 2015, Tackling reproducibility in academic preclinical drug discovery, Nat. Rev. Drug Discov., 14, 733, 10.1038/nrd4737 Fu, 2014, Improving CRISPR-Cas nuclease specificity using truncated guide RNAs, Nat. Biotechnol., 32, 279, 10.1038/nbt.2808 Garbaccio, 2016, The impact of chemical probes in drug discovery: a pharmaceutical industry perspective, Cell Chem. Biol., 23, 10, 10.1016/j.chembiol.2015.11.011 Gleeson, 2011, Probing the links between in vitro potency, ADMET and physicochemical parameters, Nat. Rev. Drug Discov., 10, 197, 10.1038/nrd3367 Griffith, 2013, DGIdb: mining the druggable genome, Nat. Methods, 10, 1209, 10.1038/nmeth.2689 Hall, 2004, Unravelling the general properties of siRNAs: strength in numbers and lessons from the past, Nat. Genet., 5, 552, 10.1038/nrg1382 Hall, 2014, Efficient exploration of chemical space by fragment-based screening, Prog. Biophys. Mol. Biol., 116, 82, 10.1016/j.pbiomolbio.2014.09.007 Hancox, 2008, The hERG potassium channel and hERG screening for drug-induced torsades de pointes, Pharmacol. Ther., 119, 118, 10.1016/j.pharmthera.2008.05.009 Hann, 2012, Finding the sweet spot: the role of nature and nurture in medicinal chemistry, Nat. Rev. Drug Discov., 11, 355, 10.1038/nrd3701 Hann, 2001, Molecular complexity and its impact on the probability of finding leads for drug discovery, J. Chem. Inf. Model., 41, 856 Højfeldt, 2014, Histone lysine demethylases as targets for anticancer therapy, Nat. Rev. Drug Discov., 12, 917, 10.1038/nrd4154 Hopkins, 2002, The druggable genome, Nat. Rev. Drug Discov., 1, 727, 10.1038/nrd892 Huber, 2017, Target engagement: shining a light, Nat. Chem. Biol., 13, 133, 10.1038/nchembio.2295 Irwin, 2015, An aggregation advisor for ligand discovery, J. Med. Chem., 58, 7076, 10.1021/acs.jmedchem.5b01105 Janzen, 2014, Screening technologies for small molecule discovery: the state of the art, Chem. Biol., 21, 1162, 10.1016/j.chembiol.2014.07.015 Jones, 2016, A fragment-based approach applied to a highly flexible target: insights and challenges towards the inhibition of HSP70 isoforms, Sci. Rep., 6, 34701, 10.1038/srep34701 Kaelin, 2017, Common pitfalls in preclinical cancer target validation, Nat. Rev. Cancer, 10.1038/nrc.2017.32 Kato, 2016, What is the true structure of D609, a widely used lipid related enzyme inhibitor?, Org. Lett., 18, 768, 10.1021/acs.orglett.6b00025 Kawamura, 2016, Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer survival, Sci. Rep., 6, 26521, 10.1038/srep26521 Kasap, 2014, DrugTargetSeqR: a genomics- and CRISPR-Cas9–based method to analyze drug targets, Nat. Chem. Biol., 10, 626, 10.1038/nchembio.1551 Kettle, 2016, Potent and selective inhibitors of MTH1 probe its role in cancer cell survival, J. Med. Chem., 59, 2346, 10.1021/acs.jmedchem.5b01760 Klaeger, 2016, Chemical proteomics reveals ferrochelatase as a common off-target of kinase inhibitors, ACS Chem. Biol., 11, 1245, 10.1021/acschembio.5b01063 Komarov, 1999, A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy, Science, 285, 1733, 10.1126/science.285.5434.1733 Kruidenier, 2012, A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response, Nature, 488, 404, 10.1038/nature11262 Lamb, 2006, The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease, Science, 313, 1929, 10.1126/science.1132939 Lanning, 2014, A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors, Nat. Chem. Biol., 10, 760, 10.1038/nchembio.1582 Lauer, M. (2016). Authentication of key biological and/or chemical resources in NIH grant applications. Open Mike. https://nexus.od.nih.gov/all/2016/01/29/authentication-of-key-biological-andor-chemical-resources-in-nih-grant-applications. Accessed May 13, 2017. Leach, 2011, Molecular complexity and fragment-based drug discovery: ten years on, Curr. Opin. Chem. Biol., 15, 489, 10.1016/j.cbpa.2011.05.008 Leeson, 2007, The influence of drug-like concepts on decision making in medicinal chemistry, Nat. Rev. Drug Discov., 6, 881, 10.1038/nrd2445 Lin, 2017, CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials, Elife, 6, 10.7554/eLife.24179 Liu, 2012, Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor, Clin. Cancer Res., 18, 510, 10.1158/1078-0432.CCR-11-1973 Liu, 2013, Developing irreversible inhibitors of the protein kinase cysteinome, Chem. Biol., 20, 146, 10.1016/j.chembiol.2012.12.006 Lounkine, 2012, Large-scale prediction and testing of drug activity on side-effect targets, Nature, 486, 361, 10.1038/nature11159 Lowe, D. (2016). In the pipeline. What does one do with these? http://blogs.sciencemag.org/pipeline/archives/2016/01/19/what-does-one-do-with-these. Lowe, D. (2017). In the pipeline. No easy road to getting rid of PAINS. http://blogs.sciencemag.org/pipeline/archives/2017/02/07/no-easy-road-to-getting-rid-of-pains. McAllister, 2016, Recent progress in histone demethylase inhibitors, J. Med. Chem., 59, 1308, 10.1021/acs.jmedchem.5b01758 McGovern, 2003, A specific mechanism of nonspecific inhibition, J. Med. Chem., 46, 4265, 10.1021/jm030266r Muroi, 2010, Application of proteomic profiling based on 2D-DIGE for classification of compounds according to the mechanism of action, Chem. Biol., 17, 460, 10.1016/j.chembiol.2010.03.016 National Cancer Institute. (2017). Office of Cancer Clinical Proteomics Research Antibody Portal. https://antibodies.cancer.gov/apps/site/default. Accessed March 16, 2017. Ndubaku, 2015, Design of selective PAK1 inhibitor G-5555: improving properties by employing an unorthodox low-pKa polar moiety, ACS Med. Chem. Lett., 6, 1241, 10.1021/acsmedchemlett.5b00398 Nicodeme, 2010, Suppression of inflammation by a synthetic histone mimic, Nature, 468, 1119, 10.1038/nature09589 Oprea, 2009, A crowdsourcing evaluation of the NIH chemical probes, Nat. Chem. Biol., 5, 441, 10.1038/nchembio0709-441 Ortiz Torres, 2015, Histone demethylase KDM5A is regulated by its reader domain through a positive-feedback mechanism, Nat. Commun., 6, 6204, 10.1038/ncomms7204 Overington, 2006, How many drug targets are there?, Nat. Rev. Drug Discov., 5, 993, 10.1038/nrd2199 Parker, 2017, Ligand and target discovery by fragment-based screening in human cells, Cell, 168, 527, 10.1016/j.cell.2016.12.029 Patel, 2012, Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro, Clin. Cancer Res., 18, 1655, 10.1158/1078-0432.CCR-11-2890 Persengiev, 2004, Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs), RNA, 10, 12, 10.1261/rna5160904 Peters, 2009, Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds, ChemMedChem, 4, 680, 10.1002/cmdc.200800411 Polier, 2013, ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system, Nat. Chem. Biol., 9, 307, 10.1038/nchembio.1212 Ponten, 2008, The human protein Atlas — a tool for pathology, J. Pathol., 216, 387, 10.1002/path.2440 Powers, 2010, Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone?, Cell Cycle, 9, 1542, 10.4161/cc.9.8.11204 Prinz, 2011, Believe it or not: how much can we rely on published data on potential drug targets?, Nat. Rev. Drug Discov., 10, 712, 10.1038/nrd3439-c1 Roncador, 2016, The European antibody network’s practical guide to finding and validating suitable antibodies for research, MAbs, 8, 27, 10.1080/19420862.2015.1100787 Rothman, 2000, Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications, Circulation, 102, 2836, 10.1161/01.CIR.102.23.2836 Santos, 2017, A comprehensive map of molecular drug targets, Nat. Rev. Drug Discov., 16, 19, 10.1038/nrd.2016.230 Schenone, 2013, Target identification and mechanism of action in chemical biology and drug discovery, Nat. Chem. Biol., 9, 232, 10.1038/nchembio.1199 Seashore-Ludlow, 2015, Harnessing connectivity in a large-scale small-molecule sensitivity dataset, Cancer Discov., 5, 1210, 10.1158/2159-8290.CD-15-0235 Sells, 2015, MLN8054 and alisertib (MLN8237): discovery of selective oral aurora a inhibitors, ACS Med. Chem. Lett., 6, 630, 10.1021/ml500409n Sharp, 2009, Thioflavin S (NSC71948) interferes with Bcl-2-associated athanogene (BAG-1)-mediated protein-protein interactions, J. Pharmacol. Exp. Ther., 331, 680, 10.1124/jpet.109.153601 Simon, 2013, Determining target engagement in living systems, Nat. Chem. Biol., 9, 200, 10.1038/nchembio.1211 Sinja, 2014, Downfall of iniparib: a PARP inhibitor that doesn’t inhibit PARP after all, J. Natl. Cancer Inst., 106, djt447, 10.1093/jnci/djt447 Steele, 2009, 2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells, Blood, 114, 1217, 10.1182/blood-2008-11-190587 Strom, 2006, Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation, Nat. Chem. Biol., 2, 474, 10.1038/nchembio809 Structural Genomics Consortium (2011). Cerep to build epigenetics screening and profiling laboratory in Toronto. http://www.thesgc.org/news/SGC_Cerep_PR_June13. Accessed March 16, 2017. Structural Genomics Consortium (2017). GSK-LSD1 A chemical probe for LSD1. http://www.thesgc.org/chemical-probes/GSK-LSD1. Accessed March 17, 2017. Su, 2016, Reader domain specificity and lysine demethylase-4 family function, Nat. Commun., 7, 13387, 10.1038/ncomms13387 Sushko, 2012, ToxAlerts: a web server of structural alerts for toxic chemicals and compounds with potential adverse reactions, J. Chem. Inf. Model., 52, 2310, 10.1021/ci300245q Swinney, 2011, How were new medicines discovered?, Nat. Rev. Drug Discov., 10, 507, 10.1038/nrd3480 Tarcsay, 2013, Contributions of molecular properties to drug promiscuity, J. Med. Chem., 56, 1789, 10.1021/jm301514n Uhlen, 2016, A proposal for validation of antibodies, Nat Methods, 13, 823, 10.1038/nmeth.3995 Vangamudi, 2015, The SMARCA2/4 ATPase domain surpasses the bromodomain as a drug target in SWI/SNF-mutant cancers: insights from cDNA rescue and PFI-3 inhibitor studies, Cancer Res., 75, 3865, 10.1158/0008-5472.CAN-14-3798 Walton, 2001, Thermodynamic and kinetic characterization of antisense oligodeoxynucleotide binding to a structured mRNA, Biophys. J., 82, 366, 10.1016/S0006-3495(02)75401-5 Walton, 2005, An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell lines, Mol. Cancer Ther., 4, 1369, 10.1158/1535-7163.MCT-04-0341 Wang, 2015, Characterization of a steroid receptor coactivator small molecule stimulator that overstimulates cancer cells and leads to cell stress and death, Cancer Cell, 28, 240, 10.1016/j.ccell.2015.07.005 Willems, 2014, Current developments in activity-based protein profiling, Bioconjug. Chem., 25, 1181, 10.1021/bc500208y Williams, 2008, An apoptosis-inducing small molecule that binds to heat shock protein 70, Angew. Chem. Int. Ed., 47, 7466, 10.1002/anie.200802801 Winter, 2015, Phthalimide conjugation as a strategy for in vivo target protein degradation, Science, 343, 1376, 10.1126/science.aab1433 Workman, 2010, Probing the probes: fitness factors for small molecule tools, Chem. Biol., 17, 561, 10.1016/j.chembiol.2010.05.013 Yap, 2015, Drugging PI3K in cancer: refining targets and therapeutic strategies, Curr. Opin. Pharmacol., 23, 98, 10.1016/j.coph.2015.05.016